JP Morgan Chase
GPCR icon

JP Morgan Chase’s Structure Therapeutics GPCR Stock Holding History

JP Morgan Chase’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$206K Sell
3,984
-208,819
-98% -$9.24M ﹤0.01% 5600
2026
Q1 		$9.35M Buy
212,803
+199,847
+1,543% +$13.7M ﹤0.01% 2749
2025
Q4 		$901K Sell
12,956
-45,192
-78% -$1.85M ﹤0.01% 4677
2025
Q3 		$1.63M Buy
58,148
+15,706
+37% +$313K ﹤0.01% 4234
2025
Q2 		$880K Sell
42,442
-91,797
-68% -$2.02M ﹤0.01% 4457
2025
Q1 		$2.32M Buy
134,239
+101,924
+315% +$2.5M ﹤0.01% 3766
2024
Q4 		$876K Sell
32,315
-1,621
-5% -$57.5K ﹤0.01% 4721
2024
Q3 		$1.49M Buy
33,936
+25,500
+302% +$986K ﹤0.01% 4228
2024
Q2 		$331K Sell
8,436
-15,995
-65% -$657K ﹤0.01% 4901
2024
Q1 		$1.05M Buy
24,431
+16,585
+211% +$699K ﹤0.01% 4320
2023
Q4 		$320K Sell
7,846
-31,713
-80% -$1.82M ﹤0.01% 5064
2023
Q3 		$1.99M Buy
+39,559
New +$1.27M ﹤0.01% 3540

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

JP Morgan Chase's GPCR Position: Q2 2026 in Review

JP Morgan Chase reduced its Structure Therapeutics (GPCR) stake by 98% in Q2 2026, selling an estimated $9.24M and leaving 3,984 shares worth $206K. The position accounts for ﹤0.01% of the portfolio, ranked #5600.

JP Morgan Chase first reported a position in GPCR in Q3 2023 and has held it in 12 quarters since. The position peaked at $9.35M in Q1 2026. 191 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • JP Morgan Chase held 3,984 shares of Structure Therapeutics worth $206K as of Q2 2026.
  • JP Morgan Chase sold 208,819 Structure Therapeutics shares in Q2 2026, an estimated $9.24M.
  • Structure Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #5600 holding.
  • JP Morgan Chase first reported a position in Structure Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • JP Morgan Chase's Structure Therapeutics position peaked at $9.35M in Q1 2026.
  • 191 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.